CardiovascularMerck
Merck Reports Positive STELLAR Trial Results for Sotatercept in Pulmonary Arterial Hypertension
BMI
Biotechnology Media Insights
Editorial Team · April 20, 2025
Merck announces positive Phase 3 STELLAR trial results showing sotatercept significantly improves exercise capacity in pulmonary arterial hypertension patients.
Merck today announced positive results from the Phase 3 STELLAR trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH) on background therapy. The trial met its primary endpoint, demonstrating a significant improvement in six-minute walk distance compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.